Novartis
NEWS
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
The two trials were evaluating the drug for reducing the rate of moderate-to-severe exacerbations compared to placebo over a 52-week period for inadequately controlled moderate-to-severe asthma (GINA Steps 4 and 5).
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Over the course of the past year, Novartis has seen significant success with the approval of five drugs that have blockbuster potential and the company sees an additional 25 potential blockbuster drugs in its pipeline.
“We are excited about entering into an agreement to acquire The Medicines Company as inclisiran is a potentially transformational medicine that reimagines the treatment of atherosclerotic heart disease and familial hypercholesterolemia,” said Vas Narasimhan, chief executive officer of Novartis.
Pharma Integrates 2019, which took place on 18th and 19th November, saw over 450 delegates from biotech, pharma, CDMOs and the supply chain come together to debate and share insights on key topics currently affecting the industry.
As usual, it was a busy week for clinical trial updates. Here’s a look.
JOBS
IN THE PRESS